Semaglutide Day 3: What Most People Get Wrong About This Stage

The biggest misconception: day 3 should feel transformative

A lot of people arrive at day 3 of semaglutide convinced they've either done something wrong (because they feel fine) or that the medicine is ruining them (because they feel queasy). Both conclusions jump too far ahead.

Semaglutide is a GLP-1 receptor agonist, it works by slowing gastric emptying and influencing hunger signals in the brain. Those effects build gradually with each weekly dose, and the 0.25 mg starting dose is deliberately low. The titration schedule exists precisely because your gut needs time to adapt. Feeling almost nothing by day 3 is not a sign the medicine isn't working; it is the medicine working exactly as designed at this stage.

Equally, mild nausea on day 3 is not a reason to stop. It is the most commonly reported early side effect across the clinical trial data, and for most people it settles within days to a couple of weeks. Understanding this distinction (between an expected adjustment and a genuine warning sign) is the most practically useful thing anyone can know at this point.

What day 3 symptoms actually tell you

Day 3 tends to coincide with the approximate peak plasma concentration window for a weekly subcutaneous injection. That means any side effects are somewhat more likely to be noticeable now than they were on semaglutide day one, when many people notice very little at all, and may ease again before the next weekly dose.

Common experiences reported at this stage (and documented in the STEP 1 trial, published in the New England Journal of Medicine) include nausea, loose stools, a reduced appetite, fatigue, or simply nothing at all. The NHS's guidance on semaglutide medicines notes that GI effects are the most frequent early reaction and that they generally improve with time.

Less commonly, people notice a mild headache or dizziness. These are also well-documented and not typically a reason for alarm on day 3. What does warrant prompt medical attention is severe, persistent stomach pain, particularly if it radiates toward your back. The MHRA highlighted acute pancreatitis as a known, if infrequent, risk with GLP-1 medicines in a January 2026 Drug Safety Update; that symptom pattern is the one to act on immediately rather than waiting out.

The practical question for most people on day 3 is simpler: eat smaller, lower-fat meals, stay well hydrated, and give it a few more days before drawing conclusions. If you are finding it hard to tolerate fluids or food, contact your prescriber rather than adjusting your dose yourself.

What day 3 is not the right moment to judge

It is genuinely too early on day 3 to assess whether semaglutide is producing results, and our guide to semaglutide day 1 explains why the very first injection sets expectations that can shape how you interpret the days that follow. Weight change at this stage, if visible on a scale, is overwhelmingly water fluctuation rather than fat loss. The STEP 1 trial measured outcomes over 68 weeks; meaningful clinical weight reduction in that data accumulated over months, not days.

If you are mid-transfer from another provider or have questions about how this fits into your treatment plan, the Wegovy treatment overview covers the full licensed pathway. For those comparing options before starting, which form of semaglutide suits weight loss is a question worth exploring early. And if cost is part of your planning, the Wegovy pricing page sets out what private treatment involves without any hidden extras.

The honest verdict on day 3: you are not behind schedule, and you are not failing if the scale hasn't moved. You are 72 hours into a treatment that is measured in months.

When to contact your prescriber, and how nume handles aftercare

At nume, every patient has access to prescriber-level aftercare seven days a week, not just when something goes wrong. Day 3 is one of those moments where a quick question to a real clinician can prevent unnecessary worry or, occasionally, catch something that genuinely needs attention. Our prescribers review each consultation personally; our clinical team is not a chatbot.

Red flags at any point early in treatment: persistent vomiting that stops you keeping fluids down, signs of a serious allergic reaction, or that severe radiating abdominal pain mentioned above. For anything else (questions about your first few days, what to eat, whether your symptoms are typical) our FAQs cover many common queries, and our support team can reach a prescriber on your behalf.

If you haven't yet started and are still weighing up whether semaglutide is right for you, a free consultation with a GPhC-registered prescriber is the appropriate first step. Semaglutide is a prescription-only medicine, and the prescriber decides suitability based on your full picture, not a checklist.